Opinion|Videos|November 4, 2024
Patient Factors and Other Considerations for Treatment Selection
Key Takeaways
- Treatment decisions are guided by disease severity, presentation, patient characteristics, and comorbid conditions, with prioritization tailored to individual patient profiles.
- Patients' expectations are integral to treatment strategies, influencing adherence and satisfaction by aligning therapy with patient goals.
Panelists discuss the factors that guide their treatment decisions for alopecia areata, including severity, presentation, patient characteristics, and comorbid conditions, while also addressing how they prioritize these factors and incorporate patients’ expectations into their treatment strategy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What factors guide your treatment decisions (severity, presentation, patient characteristics, comorbid conditions, others)?
a. Which factors do you tend to prioritize?
b. How do patients’ expectations inform your treatment strategy?
How do dosing and administration impact patient satisfaction with a treatment?
How does it impact your treatment decisions?
Advertisement
Related to this article
The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
Advertisement
Advertisement
Trending on HCPLive
1
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
2
Sarcoidosis Care Starts With Inflammation vs Fibrosis: Rohit Gupta, MD
3
ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know
4
HCPLive Five at CHEST 2026
5